XCOPRI was studied in adults with uncontrolled partial-onset seizures1
XCOPRI® (cenobamate tablets) CV was studied across 2 multicenter, randomized, double-blind, placebo-controlled studies in adult patients with partial-onset seizures with or without secondary generalization.1
concomitant antiepileptic drugs (AEDs) were not adequately controlling patients at baseline. The more frequently used AEDs were levetiracetam, lamotrigine, valproate or valproic acid, carbamazepine, oxcarbazepine, clobazam, lacosamide, and topiramate1-3
were taking 2 or more
concomitant AEDs1
was the approximate
mean duration of
epilepsy for patients
in the studies¹
was the median
baseline seizure
frequency for
patients in both studies¹
In a study of adult patients with partial-onset seizures taking XCOPRI:
2X greater seizure reduction with XCOPRI vs placebo1
The primary outcome: Median percentage reduction in 28-day seizure frequency
*Statistically significant compared with placebo.
Discover the possibility of ZERO seizures with XCOPRI1-3
Secondary outcome: Percentage of patients achieving seizure reductions of ≥75%, ≥90%, and 100%1,3
AS MANY AS 1 IN 5 PATIENTS EXPERIENCED ZERO SEIZURES1-3
Up to two-thirds of patients achieved ≥50% reduction
in seizure frequency with XCOPRI3



Demonstrated to be effective in multiple types of partial-onset seizures
XCOPRI demonstrated reductions in seizure frequency across multiple types of partial-onset seizures compared with placebo2,3,5
Secondary outcome: Median percentage reduction in 28-day seizure frequency in partial-onset seizure subtypes3,5
†Partial-onset seizures=focal seizures; simple partial=focal aware seizure; complex partial=focal impaired; secondary generalized tonic-clonic=focal to bilateral tonic-clonic.6
‡Only patients with simple partial motor seizures were included in the study.
References: 1. XCOPRI [package insert]. Paramus, NJ: SK Life Science, Inc. 2. Chung SS, French JA, Kowalski J, et al. Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures. Neurology. 2020;94(22):e2311-e2322. 3. Krauss GL, Klein P, Brandt C, et al. Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial. Lancet Neurol. 2020;19(1);38-48. 4. Data on file. SK Life Science, Inc. 5. Krauss GL, Klein P, Brandt C, et al. Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial. Lancet Neurol. 2020;19(suppl):S1-S7. 6. Fisher RS, Cross JH, French JA, et al. Operational classification of seizure types by the International League of Epilepsy: position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58(5):522-530.